SEO URLwww.firestrike.ai/deals/corstasis-therapeutics-esperion-acquisition-2026-3
acquisitionAnnounced · Mar 4, 2026BiopharmaceuticalSource · CredibleArticle · Factual
Esperion acquires Corstasis Therapeutics
David Najork · Founding Software Engineer
Published · Updated · 1 min read
Deal value
—
Target
Corstasis Therapeutics
Henderson, Nevada
Acquirer
Esperion
Full Acquisition
Status
Pending
Esperion agreed to acquire Corstasis Therapeutics. Reported deal value: Undisclosed. Status: Pending. Sector: Biopharmaceutical. Target headquarters context: Henderson, Nevada, United States.
This page summarizes publicly available information about the transaction as of 2026-03-04. Figures and status may change as filings and press coverage update.
Copy and send link X Esperion Therapeutics has signed a definitive agreement to acquire Corstasis Therapeutics to expand its cardiovascular franchise with the addition of Enbumyst, a bumetanide nasal spray
Deal timeline
Announced
Mar 4, 2026 · pharmaceutical-business-review.com
Additional milestones (proxy, vote, close) appear as filings and press updates are indexed.
Sector context
This transaction is classified in Biopharmaceutical. Figures and status may change as sources update.
Sources: pharmaceutical-business-review.com · Primary article · FireStrike proprietary index